Ospedale San Raffaele S.r.L.
|Ospedale San Raffaele S.r.L. Patent applications|
|Patent application number||Title||Published|
|20150322116||PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS - An effective||11-12-2015|
|20150299667||INFLUENZA VIRUS AND TYPE 1 DIABETES - Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities.||10-22-2015|
|20140315234||METHOD TO GENERATE DOPAMINERGIC NEURONS FROM MOUSE AND HUMAN CELLS - The present invention relates to a method for reprogramming a differentiated non neuronal cell into a dopaminergic neuron comprising the step of inducing the expression in the differentiated non neuronal cell of at least the protein encoded by the Mash1 human gene or orthologues thereof and the protein encoded by the Nurr1 human gene or orthologues thereof, expression vectors, reprogrammed dopaminergic neuron and uses thereof.||10-23-2014|
|20140086889||METHOD FOR EXPANDING CD4+CD25+T REGULATOR CELLS - A method for generating/expanding in vitro a CD4||03-27-2014|
|20130295100||MARKERS FOR ACUTE KIDNEY INJURY AND USES THEREOF - The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.||11-07-2013|
|20130289119||FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF - The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation.||10-31-2013|
|20130143204||DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF - The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease.||06-06-2013|
|20130040318||INCREASE OF MYELOID MICROVESICLES IN THE CEREBROSPINAL FLUID AS BIOMARKER OF MICROGLIA/MACROPHAGE ACTIVATION IN NEUROLOGICAL DISORDERS - The present invention relates to a method for the diagnostic and/or prognostic of a neurological disease characterized by an inflammation process in a subject comprising measuring the amount of myeloid derived microvesicles in a cerebrospinal fluid sample obtained from the subject. The invention further relates to a method for predicting and/or monitoring the efficacy of a treatment for a neurological pathology or for monitoring a neurological disease progression.||02-14-2013|
Patent applications by Ospedale San Raffaele S.r.L.